In addition, TGF-β directly suppresses immune surveillance and protects malignant cells from immune-mediated clearance10–12, and stromal TGF-β activity was recently identified as an independent determinant of tumor responsiveness to anti-PD-L1 treatment13,14. The gene discussed is TGFB1; the disease is neoplasm.